ライフサイエンスコーパス: Blastomyces dermatitidis

1 ry delivery of an attenuated vaccine against Blastomyces dermatitidis.

2 e fluid (BALF) on the interaction of BAM and Blastomyces dermatitidis.

3 infection with Strongyloides stercoralis and Blastomyces dermatitidis.

4 L in vaccine immunity to the fungal pathogen Blastomyces dermatitidis.

5 from Candida glabrata, Candida albicans, and Blastomyces dermatitidis.

6 Certain elements resembled budding cells of Blastomyces dermatitidis.

7 t are shared with Histoplasma capsulatum and Blastomyces dermatitidis.

8 al report of hard-palate infection caused by Blastomyces dermatitidis.

9 Blastomyces dermatitidis, a dimorphic fungus and the cau

10 f serum factors or MBL on the interaction of Blastomyces dermatitidis, a pulmonary fungal pathogen, w

11 fungal pulmonary infections with two agents, Blastomyces dermatitidis an extracellular pathogen, and

12 D4(+) T cells respond to a native epitope in Blastomyces dermatitidis and also in Histoplasma capsula

13 at regulates dimorphism and pathogenicity in Blastomyces dermatitidis and H. capsulatum.

14 Blastomyces dermatitidis and Histoplasma capsulatum are

15 dhesin is indispensable for pathogenicity of Blastomyces dermatitidis and is thought to promote pulmo

16 g of the molecular bases of pathogenicity in Blastomyces dermatitidis and related systemic dimorphic

17 gi Histoplasma capsulatum, Coccidioides spp, Blastomyces dermatitidis, and Paracoccidioides brasilien

18 We report results of an immunoassay for Blastomyces dermatitidis antigenuria.

19 n real-time PCR assay was developed from the Blastomyces dermatitidis BAD1 gene promoter.

20 role in phagocyte recognition and killing of Blastomyces dermatitidis, but little is known about how

21 inically important discrepancy was observed (Blastomyces dermatitidis by culture and Cryptococcus neo

22 40/CD40L interactions in vaccine immunity to Blastomyces dermatitidis by immunizing CD40(-/-) and CD4

23 The dimorphic fungal pathogen Blastomyces dermatitidis can infect immunocompetent pati

24 cally engineered, live, attenuated strain of Blastomyces dermatitidis carrying a targeted deletion at

25 e (3-week-old) mice killed nonphagocytizable Blastomyces dermatitidis cells less (25%) than did cells

26 igatus, Aspergillus terreus, Bipolaris spp., Blastomyces dermatitidis, Cladophialophora bantiana, Fus

27 to amplify DNA from Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, Paracocc

28 Recent studies showed that attenuated Blastomyces dermatitidis confers protection via T cell r

29 ast cytosol extract (YCE) crude antigen from Blastomyces dermatitidis confers T-cell-mediated resista

30 ld was found to be positive by the AccuProbe Blastomyces dermatitidis Culture ID Test (Gen-Probe Inc.

31 People infected with Blastomyces dermatitidis develop strong immunity to the

32 Humans infected with the dimorphic fungus Blastomyces dermatitidis develop strong T-lymphocyte res

33 African strains of Blastomyces dermatitidis differ from North American stra

34 We report that the pathogenic yeast of Blastomyces dermatitidis elaborates dipeptidyl-peptidase

35 Infection with Blastomyces dermatitidis elicits strong antibody respons

36 Pathogenic yeast of Blastomyces dermatitidis express a surface protein adhes

37 , a virulence factor in the dimorphic fungus Blastomyces dermatitidis, for expression in yeast and my

38 ccus neoformans, Histoplasma capsulatum, and Blastomyces dermatitidis from blood cultures.

39 Blastomyces adhesin 1), a 120-kDa protein of Blastomyces dermatitidis, functions as an adhesin, immun

40 genetically engineered attenuated strain of Blastomyces dermatitidis given s.c. as a vaccine, wherea

41 tools available for genetic manipulation of Blastomyces dermatitidis have enhanced our ability to st

42 oides posadasii, Histoplasma capsulatum, and Blastomyces dermatitidis), have soared recently, spurrin

43 Pseudallescheria boydii, Rhizopus arrhizus, Blastomyces dermatitidis, Histoplasma capsulatum, and Sp

44 vaccines to induce protection against lethal Blastomyces dermatitidis infection in mice and is far mo

45 -dependent mechanisms of vaccine immunity to Blastomyces dermatitidis infection.

46 ed immunity is pivotal in host resistance to Blastomyces dermatitidis infection.

47 Blastomyces dermatitidis is a primary fungal pathogen of

48 Blastomyces dermatitidis is a thermally induced dimorphi

49 BAD1, an adhesin and immune modulator of Blastomyces dermatitidis, is an essential virulence fact

50 BAD1, a virulence factor of Blastomyces dermatitidis, is displayed on yeast and rele

51 ulmonary infection with the dimorphic fungus Blastomyces dermatitidis often progresses and requires t

52 ved in specimens from patients infected with Blastomyces dermatitidis, Paracoccidioides brasiliensis,

53 The fungal pathogen Blastomyces dermatitidis produces an adhesin (WI-1) in y

54 Yeast forms of Blastomyces dermatitidis, Sporothrix schenckii, and Hist

55 In Blastomyces dermatitidis, the agent of blastomycosis, a

56 nsia crescens, an agent of adiaspiromycosis, Blastomyces dermatitidis, the agent of blastomycosis, an

57 Blastomyces dermatitidis, the etiologic agent of blastom

58 R senses mannan on the surface of attenuated Blastomyces dermatitidis vaccine yeast and that MR(-/-)

59 found that serum inhibitory activity against Blastomyces dermatitidis was principally mediated by alb

60 on caused by the soil-based dimorphic fungus Blastomyces dermatitidis, which is endemic throughout mu

61 Our previous studies showed that Blastomyces dermatitidis yeast activates the human compl

62 emory after vaccination with transgenic (Tg) Blastomyces dermatitidis yeasts that display a model Ag,